

13th June, 2019

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 Scrip Code: 532300	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: WOCKPHARMA
---	---

Dear Sirs,

We wish to inform the Exchanges that U. S. Food and Drug Administration ('USFDA') has carried out inspection of Bioequivalence Centre located at R&D Centre, Aurangabad from 10th - 12th June 2019, during which Bioanalytical and Quality systems of Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol ER tablets were audited. At the end of inspection, there was Nil observation (i.e. zero 483 observation), signifying that best practices were followed, in compliance to regulations. This outcome would lead approvals of ANDAs in pipeline for which Bioequivalence studies are being or will be done in the said Centre.

Kindly take the same on record please.

Thanking you,

for Wockhardt Limited



Narendra Singh
Company Secretary

